JPWO2021142127A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021142127A5 JPWO2021142127A5 JP2022541951A JP2022541951A JPWO2021142127A5 JP WO2021142127 A5 JPWO2021142127 A5 JP WO2021142127A5 JP 2022541951 A JP2022541951 A JP 2022541951A JP 2022541951 A JP2022541951 A JP 2022541951A JP WO2021142127 A5 JPWO2021142127 A5 JP WO2021142127A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- seq
- expression construct
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958563P | 2020-01-08 | 2020-01-08 | |
| US62/958,563 | 2020-01-08 | ||
| PCT/US2021/012510 WO2021142127A1 (en) | 2020-01-08 | 2021-01-07 | A method of engineering natural killer cells to target cd70-positive tumors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023509766A JP2023509766A (ja) | 2023-03-09 |
| JP2023509766A5 JP2023509766A5 (https=) | 2023-12-27 |
| JPWO2021142127A5 true JPWO2021142127A5 (https=) | 2023-12-27 |
| JP7690211B2 JP7690211B2 (ja) | 2025-06-10 |
Family
ID=76788268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541951A Active JP7690211B2 (ja) | 2020-01-08 | 2021-01-07 | Ｃｄ７０陽性腫瘍を標的化するようにナチュラルキラー細胞を操作する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230060351A1 (https=) |
| EP (1) | EP4087618A4 (https=) |
| JP (1) | JP7690211B2 (https=) |
| KR (1) | KR20220125805A (https=) |
| CN (1) | CN115243728A (https=) |
| AU (1) | AU2021205249A1 (https=) |
| BR (1) | BR112022013445A2 (https=) |
| CA (1) | CA3166832A1 (https=) |
| MX (1) | MX2022008485A (https=) |
| TW (1) | TW202135840A (https=) |
| WO (1) | WO2021142127A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023070079A1 (en) * | 2021-10-21 | 2023-04-27 | Board Of Regents, The University Of Texas System | Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereof |
| WO2023100153A1 (en) * | 2021-12-03 | 2023-06-08 | Crispr Therapeutics Ag | Use of anti-cd70 antibodies for identifying subjects susceptible for treatment with nk cell-based anti-cd70 therapy |
| JP2025511914A (ja) * | 2022-04-07 | 2025-04-16 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 操作されたナチュラルキラー細胞の活性化および増殖方法と抗体との組み合わせ |
| WO2024251290A1 (en) * | 2023-06-09 | 2024-12-12 | Suzhou Cure Genetics Biosciences Co., Limited | Engineered immune cells and uses thereof |
| CN116769722B (zh) * | 2023-07-04 | 2024-07-16 | 杭州荣谷生物科技有限公司 | 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2686347T3 (en) * | 2011-03-16 | 2018-06-25 | Argenx Bvba | Antibodies against CD70 |
| GB201206559D0 (en) * | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| ES3063961T3 (en) * | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| CN113968913A (zh) * | 2014-12-08 | 2022-01-25 | 美国卫生和人力服务部 | 抗cd70嵌合抗原受体 |
| KR102039189B1 (ko) * | 2016-03-23 | 2019-11-01 | 서울대학교산학협력단 | 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도 |
| US20190161542A1 (en) * | 2016-08-01 | 2019-05-30 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| WO2018195339A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| KR102780406B1 (ko) * | 2018-02-01 | 2025-03-17 | 화이자 인코포레이티드 | Cd70을 표적으로 하는 키메라 항원 수용체 |
| MX2020011697A (es) * | 2018-05-03 | 2020-12-10 | Univ Texas | Células exterminadoras naturales diseñadas para expresar receptores de antígeno quimérico con bloqueo de punto de control inmunitario. |
| MX2020012927A (es) * | 2018-06-01 | 2021-03-25 | Univ Southern California | Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular. |
| CN109880802B (zh) * | 2018-11-30 | 2022-12-13 | 北京美康基免生物科技有限公司 | 一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
-
2021
- 2021-01-07 US US17/758,094 patent/US20230060351A1/en active Pending
- 2021-01-07 KR KR1020227027290A patent/KR20220125805A/ko active Pending
- 2021-01-07 EP EP21738525.1A patent/EP4087618A4/en active Pending
- 2021-01-07 JP JP2022541951A patent/JP7690211B2/ja active Active
- 2021-01-07 CN CN202180019200.XA patent/CN115243728A/zh active Pending
- 2021-01-07 MX MX2022008485A patent/MX2022008485A/es unknown
- 2021-01-07 AU AU2021205249A patent/AU2021205249A1/en active Pending
- 2021-01-07 WO PCT/US2021/012510 patent/WO2021142127A1/en not_active Ceased
- 2021-01-07 CA CA3166832A patent/CA3166832A1/en active Pending
- 2021-01-07 BR BR112022013445A patent/BR112022013445A2/pt unknown
- 2021-01-08 TW TW110100801A patent/TW202135840A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7300763B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| US20220347219A1 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| US12404338B2 (en) | Anti CD30 chimeric antigen receptor and its use | |
| US20230092130A1 (en) | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof | |
| CN109385403B (zh) | 靶向gpc3的car nk细胞 | |
| JP2020513839A5 (https=) | ||
| BR112016023500B1 (pt) | Ácido nucleico que codifica um receptor quimérico, método para a preparação de uma célula hospedeira e usos do mesmo | |
| CN109280086B (zh) | 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体 | |
| JP2017512054A (ja) | 三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用 | |
| WO2020057641A1 (zh) | 表达有趋化因子的细胞及用途 | |
| KR20210018838A (ko) | 유전자 조작된 세포 및 응용 | |
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities | |
| WO2021057906A1 (zh) | 表达il-15的免疫效应细胞 | |
| CN110468105A (zh) | 表达il-18r结合蛋白的免疫效应细胞 | |
| WO2024051831A1 (zh) | 组成型嵌合细胞因子受体及表达其的免疫细胞及应用 | |
| WO2021027785A1 (zh) | 共表达趋化因子受体的免疫效应细胞 | |
| US20220056411A1 (en) | Methods for isolating cd8+ selected t cells | |
| JP2022513164A (ja) | 胎盤由来同種ｃａｒ－ｔ細胞およびその使用 | |
| CN110438082A (zh) | 表达il-21r结合蛋白的免疫效应细胞 | |
| JPWO2021142127A5 (https=) | ||
| CN118510901A (zh) | 嵌合衔接子多肽 | |
| JPWO2023278811A5 (https=) | ||
| CN116411025A (zh) | Sirt1-7蛋白在免疫治疗中的应用 | |
| WO2022033483A1 (zh) | 多功能的免疫效应细胞及其应用 | |
| JPWO2022098914A5 (https=) |